(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 13.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Mannkind's revenue in 2025 is $301,736,000.On average, 4 Wall Street analysts forecast MNKD's revenue for 2025 to be $98,151,316,083, with the lowest MNKD revenue forecast at $96,313,414,357, and the highest MNKD revenue forecast at $100,087,402,877. On average, 4 Wall Street analysts forecast MNKD's revenue for 2026 to be $113,513,290,332, with the lowest MNKD revenue forecast at $101,345,399,051, and the highest MNKD revenue forecast at $124,839,244,661.
In 2027, MNKD is forecast to generate $137,897,858,599 in revenue, with the lowest revenue forecast at $126,216,903,886 and the highest revenue forecast at $159,774,718,885.